Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.45
Ask: 1.55
Change: 0.00 (0.00%)
Spread: 0.10 (6.897%)
Open: 1.50
High: 1.50
Low: 1.475
Prev. Close: 1.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genedrive's CYP2C19 ID Kit included in UK's NICE assessment

Mon, 22nd Aug 2022 11:48

(Alliance News) - Genedrive PLC on Monday said the UK's National Institute for Health & Clinical Excellence has begun an evaluation of CYP2C19 genotype testing for Clopidogrel treatment.

The Manchester-based molecular diagnostics company said that its CYP2C19 ID Kit, which is currently in development, has been included in the new NICE Diagnostics Assessment Programme.

Clopidogrel is a drug that is given to ischemic stroke patients to prevent further clot formation. The CYP2C19 test is a rapid point of care test, which provides guidance on which patients will respond to Clopidogrel.

"The CYP2C19 gene is involved in a metabolic pathway in the liver that converts Clopidogrel to its active form. Clopidogrel is less effective in individuals with certain genetic CYP2C19 variants because they do not metabolize Clopidogrel fully," Genedrive explained.

The company also said that its Point of Care genetic screening tests are now included in new NICE reviews, following the MT-RNR1 DAP announcement in June.

Chief Executive Officer David Budd said: "The review is very timely for us, given the current development of our new CYP2C19 ID Point of Care test. The clinical landscape for genotype-guided antiplatelet therapy has advanced in the last two years, with a growing number of pharmacogenetic clinical bodies recommending genotype-guided Clopidogrel administration."

Shares in Genedrive were down 1.6% to 17.95 pence each in London on Monday midday.

By Sophie Rose; sophierose@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 May 2020 15:35

UK DIRECTOR DEALINGS SUMMARY: Silence CFO Sells GBP360,000 Worth

UK DIRECTOR DEALINGS SUMMARY: Silence CFO Sells GBP360,000 Worth

Read more
5 May 2020 18:44

Genedrive Placing Succeeds In Hitting GBP7 Million Placing Goal

Genedrive Placing Succeeds In Hitting GBP7 Million Placing Goal

Read more
5 May 2020 17:04

Genedrive To Raise GBP7 Million To Fund Assay Test Development

Genedrive To Raise GBP7 Million To Fund Assay Test Development

Read more
4 May 2020 18:41

Genedrive Hepatitis Test Kit Prequalified By World Health Organisation

Genedrive Hepatitis Test Kit Prequalified By World Health Organisation

Read more
1 May 2020 16:17

Genedrives completes manufacturing milestone for Covid-19 test

(Sharecast News) - Near-patient molecular diagnostics company Genedrive has completed the last significant manufacturing milestone in the co-development of the 'Genedrive 96 SARS-CoV-2' kit with Cytiva, it announced on Friday.

Read more
1 May 2020 13:28

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Read more
24 Apr 2020 14:47

Inspiration Healthcare Signs Distribution Agreement With Genedrive

Inspiration Healthcare Signs Distribution Agreement With Genedrive

Read more
20 Apr 2020 11:40

Genedrive To Collaborate On Rapidly Manufactured Covid-19 Test

Genedrive To Collaborate On Rapidly Manufactured Covid-19 Test

Read more
25 Mar 2020 14:57

Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests

Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests

Read more
4 Feb 2020 12:22

Genedrive Shares Plunge 45% As Loss Widens On Shipping Order Delays

Genedrive Shares Plunge 45% As Loss Widens On Shipping Order Delays

Read more
28 Jan 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
3 Dec 2019 10:10

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Read more
3 Dec 2019 09:39

Genedrive upbeat on latest results from RNR1 kit testing

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Tuesday that in its case-control clinical validation, the antibiotic-induced hearing loss assay - the 'Genedrive MT-RNR1 ID' kit - achieved a diagnostic sensitivity of 100% and specificity of 100% on a cohort of 303 samples.

Read more
18 Nov 2019 16:00

Genedrive infant hearing loss test gets CE mark

(Sharecast News) - Molecular diagnostics company Genedrive announced on Monday that its antibiotic-induced hearing loss test, the 'Genedrive MT-RNR1 ID' kit, has obtained CE marking.

Read more
18 Nov 2019 11:15

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.